Tottenham announced they had “remastered” their brand identity. For anyone left confused by that phrase, don’t worry, you ...

Sanofi (SNY) has released an update. Don't Miss our Black Friday Offers: Sanofi’s Sarclisa received a positive recommendation from the EMA’s CHMP for treating newly diagnosed multiple myeloma patients ...

One new mission involves collecting Purple Pumpkins spread across the map. However, due to the area's vastness, acquiring all 25 of them can be quite a challenge. To help you complete the quest ...

Today's fashion forecast looks deep purple with light sparkling showers brought to us by the ever-so-stunning Esha Gupta in an embellished lehenga. The Bollywood star's rich and regal ensemble has ...

Powered by PandaOmics, Insilico’s proprietary generative biology AI platform, the joint R&D team comprising Insilico Medicine and Sanofi colleagues focused on highly novel targets known to be ...

French pharma giant Sanofi is selling off its consumer healthcare business Opella. US-based investment firm Clayton, Dubilier & Rice (CD&R) is to take a controlling 50% stake, while Sanofi will retain ...

(RTTNews) - Sanofi announced that Beyfortus (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon this fall. The administration ...

There’s one thing upon which Kamala Harris and Donald Trump readily agree: Wisconsin will play a vital role in who wins the election. In a July speech in Milwaukee, Harris asserted, “The path ...

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Sell rating on Sanofi (SNYNF – Research Report), with a price target of €90.00. The company’s shares closed ...

Here's how the Purple Hybrid Premier 3 mattress has held up after half a decade and my thoughts on whether you should consider Purple for your next mattress. Owen Poole, a Certified Sleep Science ...

Sanofi (NASDAQ:SNY) shares gained on Friday after the French pharma giant exceeded analysts' estimates with its Q3 thanks mainly to earlier-than-anticipated vaccine sales and a 22% YoY rise in ...

Despite Merck & Co. homing in on approval for its infant respiratory syncytial virus (RSV) antibody clesrovimab, Sanofi—which last year won its own nod for its AstraZeneca-partnered RSV ...